Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats

被引：107
作者：
Entenza, JM
Loeffler, JM
Grandgirard, D
Fischetti, VA
Moreillon, P
机构：
[1] Univ Lausanne, Dept Fundamental Microbiol, CH-1015 Lausanne, Switzerland
[2] Rockefeller Univ, Lab Bacterial Pathogenesis, New York, NY 10021 USA
[3] Univ Bern, Inst Infect Dis, CH-3010 Bern, Switzerland
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2005年 / 49卷 / 11期
关键词：
D O I：
10.1128/AAC.49.11.4789-4792.2005
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Cpl-1, a pneumococcal phage lytic enzyme, was tested in rats with experimental endocarditis due to Streptococcus pneamoniae WB4. High-dose regimen Cpl-1 eliminated pneumococci from blood within 30 min and decreased bacterial titers in vegetations (> 4 log(10) CFU/g) within 2 h. Rapid bacterial lysis induced by Cpl-1 treatment increased cytokine secretion noticeably.
引用
收藏
页码：4789 / 4792
页数：4
相关论文
共 10 条
[1]   Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis [J].
Cottagnoud, P ;
Cottagnoud, M ;
Acosta, F ;
Flatz, L ;
Kühn, F ;
Stucki, A ;
Entenza, J .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2003, 22 (11) :656-662
[2]   Synergistic killing of streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance [J].
Djurkovic, S ;
Loeffler, JA ;
Fischetti, VA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :1225-1228
[3]   Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance [J].
Entenza, JM ;
Que, YA ;
Vouillamoz, J ;
Glauser, MP ;
Moreillon, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) :3076-3083
[4]   SIMULATION OF AMOXICILLIN PHARMACOKINETICS IN HUMANS FOR THE PREVENTION OF STREPTOCOCCAL ENDOCARDITIS IN RATS [J].
FLUCKIGER, U ;
MOREILLON, P ;
BLASER, J ;
BICKLE, M ;
GLAUSER, MP ;
FRANCIOLI, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (12) :2846-2849
[5]  
HERAIEF E, 1982, INFECT IMMUN, V37, P127
[6]   Streptococcus pneumoniae:: Epidemiology and patterns of resistance [J].
Jacobs, MR .
AMERICAN JOURNAL OF MEDICINE, 2004, 117 :3-15
[7]   Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model [J].
Jado, I ;
López, R ;
García, E ;
Fenoll, A ;
Casal, J ;
García, P .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (06) :967-973
[8]   Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillin-sensitive and -resistant Streptococcus pneumoniae strains [J].
Loeffler, JM ;
Fischetti, VA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) :375-377
[9]   Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia [J].
Loeffler, JM ;
Djurkovic, S ;
Fischetti, VA .
INFECTION AND IMMUNITY, 2003, 71 (11) :6199-6204
[10]   Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin [J].
Schrag, SJ ;
McGee, L ;
Whitney, CG ;
Beall, B ;
Craig, MS ;
Choate, ME ;
Jorgensen, JH ;
Facklam, RR ;
Klugman, KP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (08) :3016-3023
1